Genzyme/Roche bought Ilex Oncology for $26 a share.
or for $1 billion in equity. The original co-founder/chief scientific officer's current oncology biotech trades for 28 cents (tiny $6 million market cap) and has two blockbuster cancer compounds. Tight float and a ceo that bought 175,000 shares last year in the open market + $65 million in milestones coming in. My target for OVIT in 2012 is $3-4 a share. http://www.youtube.com/watch?v=Mh_RZMh-xcU www.oncovista.com ticker: ovit